American Academy of Allergy, Asthma & Immunology Annual Meeting 2026

Oral Abstract:
VITESSE Phase 3 Study: Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children 4 Through 7 Years of Age

View Presentation